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SUMMARY. Highly pathogenic avian influenza (HPAI) clade 2.3.4.4 viruses from the H5 goose/Guangdong lineage caused a
major outbreak in poultry in the United States in 2015. Although the outbreak was controlled, vaccines were considered as an
alternative control method, and new vaccines were approved and purchased by the U.S. Department of Agriculture National
Veterinary Stockpile for emergency use. In this study, we evaluated the efficacy of two of these vaccines in protecting Pekin ducks
(Anas platyrhynchos var. domestica) against challenge with a H5N2 HPAI poultry isolate. A recombinant alphavirus–based vaccine
and an inactivated adjuvanted reverse genetics vaccine, both expressing the hemagglutinin gene of a U.S. H5 clade 2.3.4.4 isolate
(A/Gyrfalcon/Washington/41088-6/2014 H5N8), were used to immunize the ducks. The vaccines were given either as single
vaccination at 2 days of age or in a prime-boost strategy at 2 and 15 days of age. At 32 days of age, all ducks were challenged with
A/turkey/Minnesota/12582/15 H5N2 HPAI virus clade 2.3.4.4. All ducks from the nonvaccinated challenge control group became
infected and shed virus; one duck in this group presented mild ataxia, and a second duck died. No mortality or clinical signs were
observed in vaccinated and challenged ducks, with the exception of one duck presenting with mild ataxia. Both vaccines, regardless
of the vaccination strategy used, were immunogenic in ducks and reduced or prevented virus shedding after challenge. In
conclusion, good protection against H5Nx infection was achieved in ducks vaccinated with the vaccines examined, which were
homologous to the challenge virus, with prime-boost strategies conferring the best protection against infection.
RESUMEN. Eficacia de dos vacunas con licencia contra influenza aviar H5 frente a un desaf´ıo con un virus de la influenza aviar
altamente pato´geno H5N2 en patos dome´sticos de los Estados Unidos del an˜o 2015 y del clado 2015 2.3.4.4.
Los virus de la influenza aviar altamente pato´gena (HPAI) 2.3.4.4 del linaje H5 ganso/Guangdong causaron un brote importante en
la avicultura de los Estados Unidos en el an˜o 2015. Aunque el brote fue controlado, las vacunas se consideraron un me´todo de control
alternativo y nuevas vacunas fueron aprobadas y adquiridas por la Reserva Nacional Veterinaria del Departamento de Agricultura de
los Estados Unidos para uso en caso de emergencia. En este estudio, se evaluo´ la eficacia de dos de estas vacunas en la proteccio´n de
patos Pekin frente al desaf´ıo con un aislamiento aviar H5N2 de alta patogenicidad. Se utilizaron una vacuna recombinante basada en
alfavirus y una vacuna generada por gene´tica inversa, inactivada y con adyuvante, ambas expresando el gene de la hemaglutinina de un
aislamiento H5 clado 2.3.4.4 (A/Gyrfalcon/Washington/41088-6/2014 H5N8), para inmunizar los patos. Las vacunas se
administraron como vacunacio´n u´nica a los 2 dı´as de edad o con un programa de primovacunacio´n y refuerzo a los 2 y 15 dı´as de
edad. A los 32 dı´as de edad, todos los patos fueron desafiados con el virus de alta patogenicidad A/turkey/Minnesota/12582/15 H5N2
clado 2.3.4.4. Todos los patos del grupo control no vacunado y desafiado se infectaron y excretaron al virus; un pato en este grupo
presento´ ataxia leve y un segundo pato murio´. No se observo´ mortalidad o signos cl´ınicos en patos vacunados y desafiados, con la
excepcio´n de un pato que presento´ ataxia leve. Ambas vacunas, independientemente de la estrategia de vacunacio´n utilizada, fueron
inmunoge´nicas en patos y redujeron o evitaron la diseminacio´n del virus despue´s del desaf´ıo. En conclusio´n, se logro´ una buena
proteccio´n contra la infeccio´n por H5N2 en los patos vacunados con las vacunas evaluadas, las cuales eran homo´logas al virus de
desaf´ıo y las estrategias de primovacunacio´n y refuerzo confirieron la mejor proteccio´n contra la infeccio´n.
Key words: Highly pathogenic avian influenza, H5, clade 2.3.4.4, ducks, vaccines, vaccination
Abbreviations: A ¼ alphavirus; AIV ¼ avian influenza virus; ANOVA ¼ analysis of variance; CL ¼ cloacal; dpc ¼ days
postchallenge; ECE¼ embryonating chicken eggs; EID50¼50% egg infective dose; ELISA¼ enzyme-linked immunosorbent assay;
Gs/GD¼ A/goose/Guangdong/1/1996; GyrF/14¼ A/Gyrfalcon/Washington/41088-6/2014 H5N8; HA¼ hemagglutinin; HAU
¼ hemagglutinin units; HI ¼ hemagglutination inhibition; HPAI ¼ highly pathogenic avian influenza; I ¼ inactivated; OP ¼
oropharyngeal; qRTT-PCR¼Real time quantitative reverse transcription polymerase chain reaction; RNA¼ ribonucleic acid; SPF
¼ specific pathogen free; Tk/15¼A/turkey/Minnesota/12582/2015 H5N2; USDA¼U.S. Department of Agriculture; USNPRC¼
U.S. National Poultry Research Center
The H5N1 A/goose/Guangdong/1/1996 (Gs/GD) lineage of
highly pathogenic avian influenza (HPAI) virus continues to spread
across the world, affecting wild birds, poultry, and humans. Despite
efforts to control these viruses, they continue to evolve, leading to
the emergence of multiple sublineages and the generation of
reassortant H5 strains with novel gene constellations, including
H5N2, H5N5, H5N6, and H5N8 subtypes. In late autumn 2014,
H5N8 HPAI viruses were detected in Siberia, several countries in
Europe, in South Korea, and in Japan (8,32). Concurrently, this
virus was detected in the United States (3). In addition, anotherDCorresponding author. E-mail: Mary.Pantin-Jackwood@ars.usda.gov
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novel reassortant H5 HPAI clade 2.3.4.4 virus (H5N2) was
identified as the cause of an outbreak in poultry in Canada during
November 2014 (16) and later detected in the United States in wild
waterfowl, raptors, and backyard poultry, including domestic
waterfowl (29). From March to June 2015, this H5N2 virus
predominated in the United States, with extensive interfarm
transmission occurring in the midwestern region (27). The
magnitude of the H5N2 HPAI outbreak and the associated risk of
reintroduction of the virus in commercial poultry by migratory wild
birds led to the inclusion of several licensed vaccines that were likely
protective against clade 2.3.4.4 H5N2 as part of U.S. National
Veterinary Stockpile (7,25). These vaccines included an inactivated
reverse genetics H5N1 vaccine and a recombinant alphavirus–based
replicon vaccine, both expressing the U.S. H5N8 index virus (A/
gyrfalcon/Washington/2014 H5N8) hemagglutinin (HA) gene
modified to have a low pathogenic avian influenza cleavage site.
The main difference between the alphavirus-based replicon vaccine
and other viral vectored vaccines is that the alphavirus is replication
restricted because it does not contain all the genes necessary for viral
packaging. Therefore, the vaccine has characteristics of a live vaccine
in that it induces humoral and cell-mediated immunity, but it has
the safety of an inactivated vaccine, so for regulatory purposes, it is
considered an inactivated vaccine (9,30).
Domestic ducks are a small but important sector of the poultry
industry affected by the H5Nx HPAI outbreaks (22). Domestic
ducks are also common backyard poultry frequently in contact with
wild waterfowl, thus serving as a possible bridge between avian
influenza virus (AIV)–infected wild birds and other poultry species.
Consequently, reducing the risk of virus infection in domestic ducks
is considered crucial for controlling the spread of H5Nx Gs/GD
lineage viruses. Vaccination can reduce viral shedding among
infected birds and thereby decrease transmission rates, which is
especially important when implementation of enhanced biocontain-
ment measures is impractical (26).
In a previous study, we showed that Gs/GD lineage H5N2 and
H5N8 HPAI viruses can easily infect domestic waterfowl and
transmit to contact birds (15). The disease is mostly asymptomatic,
but infected ducks shed virus for several days, representing a risk to
other poultry species. The majority of the vaccines used in domestic
ducks to protect against Gs/GD lineage H5N1 HPAI viruses have
been oil emulsion inactivated vaccines. The seed strains for these
types of vaccines can be naturally occurring low pathogenic avian
influenza strains, but because of antigenic drift, seed strains are more
likely to be viruses made by using reverse genetics techniques that
change the HPAI virus to be low pathogenic. Both commercially
available and experimental vaccines have been evaluated in ducks
(14). However, there is insufficient information on the effectiveness
of H5 HPAI vaccination against the more recent H5Nx viruses in
domestic duck species to help guide disease control programs.
The objective of this study was to examine the efficacy in
domestic ducks of two vaccines licensed in the United States for
their potential in controlling H5Nx clade 2.3.4.4 HPAI viruses
in poultry. A commercial H5 vector vaccine based on RNA
replicon system, which uses an alphavirus backbone to express the
H5 gene from a HA clade 2.2.3.4 H5N8 HPAI virus, and an
inactivated H5 vaccine also based on the same HA were used to
determine protection of Pekin ducks (Anas platyrhynchos var.
domestica) from challenge with a H5N2 HPAI virus from the
2015 U.S. outbreak.
MATERIALS AND METHODS
Vaccines and challenge virus. The H5N1 seed strain was produced
by reverse genetics technology that included a HA gene from clade
2.3.4.4, A/Gyrfalcon/Washington/41088-6/2014 H5N8 (GyrF/14) that
had a modified cleavage site compatible with a low pathogenic AIV. The
NA (N1 subtype) and internal genes were from an egg-adapted A/
Puerto Rico/08/1934 (H1N1) strain, and the rescued virus was shown
to be low pathogenic (5). Virus stock was prepared in specific-pathogen-
free (SPF) embryonating chicken eggs (ECE), followed by inactivation
with betapropiolactone and diluted to provide a concentration of 512
hemagglutinin units (HAU) per 0.2 ml when mixed (70/30) with
Montanide ISA VG70 oil emulsion adjuvant (SEPPIC Inc., Fairfield,
NJ) according to the manufacturers’ recommendations. The recombi-
nant alphavirus replicon–based vaccine (SirraVax, Harrisvaccines, Inc.,
Ames, IA, conditionally approved by the U.S. Department of
Agriculture [USDA)]) (31) also carries the modified HA gene from
GyrF/14.
The HPAI A/turkey/Minnesota/12582/2015 H5N2 (Tk/15) clade
2.3.4.4 virus, obtained from the virus repository at Southeast Poultry
Research Laboratory, USDA–Agricultural Research Service (Athens,
GA) was used as the challenge virus. Virus stock was amplified in SPF
ECE, and virus titer was determined by 50% egg infective dose (EID50).
The experiment was performed in biosecurity level 3–enhanced facilities
in accordance with procedures approved by the U.S. National Poultry
Research Center (USNPRC) Institutional Biosecurity Committee.
Experimental design. Newly hatched Pekin ducks (A. platyrhynchos
var. domestica) were obtained from a commercial hatchery. Serum
samples were collected from 15 ducks to ascertain that the birds were
serologically negative for antibodies to the nucleoprotein of influenza A
viruses, as determined by the commercial competitive ELISA test
FlockCheck AI (IDEXX Laboratories, Westbrook, ME). At 2 days of
age, ducks were randomly divided into seven groups of 10 ducks each
(Table 1). Group 1 served as nonvaccinated nonchallenged controls.
Table 1. Vaccination strategy in ducks. Ducklings were divided into groups (n¼ 10 per group) and vaccinated with a recombinant alphavirus–
based replicon vaccine (A vaccine) or an adjuvanted inactivated reverse genetics vaccine (I vaccine) by using a single or prime-boost strategy. At 32
days of age, ducks were challenged with A/turkey/Minnesota/12582/15 H5N2 HPAI virus and monitored daily for clinical signs.
Experimental groups Treatment
Age (days)
2 15 32 42
1 Nonvaccinated, nonchallenged — — Serology Serology
2 Nonvaccinated, challenged — — Serology and virus challenge Serology
3 Vaccinated (A vaccine) A vaccine — Serology and virus challenge Serology
4 Vaccinated (I vaccine) I vaccine — Serology and virus challenge Serology
5 Vaccinated (A þ A vaccine) A vaccine A vaccine Serology and virus challenge Serology
6 Vaccinated (I þ I vaccine) I vaccine I vaccine Serology and virus challenge Serology
7 Vaccinated (A þ I vaccine) A vaccine I vaccine Serology and virus challenge Serology
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Group 2 served as nonvaccinated challenged controls. The other five
groups were vaccinated subcutaneously in the nape of the neck with 0.2
ml of the alphavirus (A) replicon vaccine (107 particles per dose, as
recommended by manufacturer) or of the recombinant inactivated (I)
vaccine (512 HAU) at 2 days or 2 and 15 days of age (Table 1). Groups
3 and 4 were vaccinated only at 2 days of age with vaccine A or vaccine
I, respectively. Groups 5 and 6 additionally received a boost with the
same vaccines at 15 days of age (Group 5: A-A; Group: 6 I-I). Group 7
was vaccinated at 2 days with vaccine A and at 15 days with vaccine I (A-
I). At 32 days of age, blood samples were collected from all vaccinated
ducks for serology, and all ducks were inoculated intranasally with 106.0
EID50 of the Tk/15 challenge HPAI virus. Ducks were observed daily
for clinical signs and mortality. Oropharyngeal (OP) and cloacal (CL)
swabs were collected at 3, 5, 7, and 10 days postchallenge (dpc) for
determining viral shedding. At the end of the experiment (10 dpc),
blood was collected from all surviving ducks for serology, and ducks
were euthanatized by injection of sodium pentobarbital (5 g/ml). This
study and associated procedures were reviewed and approved by the
USNPRC Institutional Animal Care and Use Committee.
Serology. Hemagglutination inhibition (HI) tests were performed to
determine antibody responses against vaccines and challenge viruses in
the serum samples collected before challenge and at 10 dpc (12).
Inactivated GyrF/14 virus was used as HI antigen. HI titers are reported
as log 2 values, with .3 log 2 (1:8) being the minimum titer considered
as positive.
Determination of virus shedding. OP and CL swabs were collected
in sterile brain heart infusion medium and kept frozen at70 C. Total
RNA was extracted by using MagMAXe-96 AI/ND Viral RNA
Isolation Kitt (Ambion, Inc., Austin, TX) following the manufacturer’s
instructions. Real time quantitative reverse transcription polymerase
chain reactions (qRRT-PCR)targeting the influenza virus M gene (21)
were conducted by using AgPath-ID One-Step RT-PCR Kit (Ambion,
Inc.) and the ABI 7500 Fast Real-Time PCR system (Applied
Biosystem, Carlsbad, CA). For viral quantification, a standard curve
was established with viral RNA extracted from the same titrated stock of
challenge virus. Results were reported as EID50 per milliliter equivalents,
with the lower limit of detection being 102 EID50/ml.
Statistical analysis. All data analyses were performed by using Prism
Version 7 software (GraphPad Software Inc., San Diego, CA). One-way
ANOVA with Tukey posttest was used to analyze virus titers in swabs.
For statistical purposes, all OP and CL swabs from which viruses were
not detected were given a numeric value of 101.9 EID50/ml. These values
were given on the basis of a detectable level of virus in these samples
dependent on the methods used. Statistical significance was set at P ,
0.05.
RESULTS
Clinical signs. The nonvaccinated nonchallenged birds did not
show clinical signs. One duck from the nonvaccinated group
challenged with the Tk/15 HPAI virus presented mild ataxia starting
at 3 dpc, and a second duck was found dead at 4 dpc. The remaining
ducks in this group did not show clinical signs of disease. One duck
from the group vaccinated with the A vaccine showed mild ataxia
starting at 4 dpc. One duck from the I-I vaccinated group and one
from the A-I group had to be euthanatized at 8 dpc because of leg
problems unrelated to infection. No clinical signs were present in
any of the remaining vaccinated ducks.
Serum antibody responses to vaccination and infection. Antibody
responses following vaccination were tested prior to challenge and at
10 dpc by using the inactivated GyrF/14 virus as antigen in the HI
test (same HA as the vaccines used). None of the nonvaccinated
ducks and ducks that received the single A or I vaccines had positive
prechallenge HI titers (Fig. 1a). Also, 50% to 100% of the prime-
boosted vaccinated ducks developed positive prechallenge HI titers
(3 log 2). Titers between these three groups were not significantly
different (P, 0.01), but all birds vaccinated with A-I seroconverted,
contrary to birds vaccinated with A-A and I-I in which 8 of 10 or 5
of 10, respectively, seroconverted.
Following challenge, four of nine of the unvaccinated challenged
ducks had positive titers (4–5 log 2) when examined at 10 dpc (Fig.
1b). All ducks vaccinated with the A vaccine and 9 of 10 of the
ducks vaccinated with the I vaccine seroconverted (titers of 4–10
log 2 and 5–9 log 2 respectively). In the prime-boosted vaccine
groups (A-A, I-I, and A-I) 8 of 10, 6 of 9, and 7 of 9 of the ducks
seroconverted, respectively. Titers between these three groups were
not significantly different. Although titers were also not different
between groups that received the A, I, or A-A vaccines, there were
significantly lower titers in the I-I and the A-I groups when
compared with the A and I vaccine groups (P , 0.01).
Virus shedding after challenge with H5N2 clade 2.3.4.4 virus.
Virus shedding was monitored by quantification of viral RNA in OP
and CL samples collected at different time points after virus
Fig. 1. Mean HI titers (log 2) in ducks vaccinated with a recombinant alphavirus–based replicon vaccine (A vaccine) and an inactivated reverse
genetics vaccine (I vaccine) given as single vaccination or in a prime-boost regime. Serum was collected at 32 days of age, prechallenge (Fig. 1a), and
10 dpc with A/turkey/Minnesota/12582/15 H5N2 HPAI virus (Fig. 1b) to examine the antibody responses. Bars represent standard deviation within
groups. HI tests conducted using GyrF/14 virus as antigen in the HI test (virus homologous to the vaccines used). Different superscript lowercase
letters denote significant difference for mean HI titers between groups, P , 0.05. NV-NC ¼ nonvaccinated nonchallenged controls; NV-C ¼
nonvaccinated challenged controls.
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challenge (Table 2; Fig. 2). Virus replicated and was shed efficiently
from the upper respiratory and intestinal tract of the nonvaccinated
challenged ducks, with a mean OP titer of 5.8 log 10 EID50 and a
mean CL titer of 3.6 log 10 EID50 at 3dpc. Most ducks from this
group were still shedding virus at 10 dpc.
In contrast, no virus shedding was detected in ducks twice
vaccinated with the I-I and A-I prime-boost strategy, and only one
duck from the A-A vaccine group shed low titers of virus by the OP
and CL route. Although virus shedding was detected in some ducks
vaccinated with the single A or I vaccines, no significant difference in
virus titers was found between these groups and the groups of ducks
receiving the prime-boost vaccine strategy. OP and CL virus titers
for all vaccinated groups and at all time points were significantly
lower than virus titers from the nonvaccinated challenge group.
On the basis of virus shed, ducks vaccinated with the I-I and A-I
prime-boost strategy did not become infected. Nine out of 10 ducks
vaccinated with A-A were also protected from infection; however, on
the basis of serology at 10 dpc, some boost effect was observed in
two ducks, indicating possible low virus replication. Most ducks
vaccinated with the single A or I vaccines shed virus (eight and nine,
respectively), and a boost effect on HI titers was observed at 10 dpc
when compared with prechallenge HI titers.
DISCUSSION
Domestic waterfowl have an important role in the maintenance of
H5Nx HPAI viruses. Despite control efforts, H5Nx HPAI viruses
continue to circulate within various poultry populations, including
domestic ducks. During the U.S. outbreak, H5N8 and H5N2 HPAI
viruses were detected in backyard waterfowl (28) and H5N8 HPAI
viruses in commercial duck facilities (19). Other clade 2.3.4.4 H5Nx
HPAI viruses have also caused outbreaks in domestic ducks in
several countries around the world (2,10). Many Gs/GD lineage
H5N1 HPAI viruses and, recently, clade 2.3.4.4 Gs/GD–derived
H5Nx viruses have caused disease and death in wild and domestic
ducks (2,6,10,13,15,18,19,23), and both sick and asymptomatic-
infected ducks shed high amounts of virus into the environment,
favoring transmission and potential outbreaks in commercial
poultry. In this study, we evaluated the efficacy of a recombinant
alphavirus–based replicon vaccine (A vaccine) and an adjuvanted
and inactivated reverse genetics vaccine (I vaccine) in protecting
Pekin ducks against challenge with a H5N2 HPAI clade 2.3.4.4
virus.
All nonvaccinated ducks challenged with the Tk/15 HPAI virus
became infected. The virus replicated to high titers in most ducks,
and mild neurologic signs or mortality was observed in two ducks.
This same virus also caused low mortality and was shed in high titers
in mallards and had a similar high infectivity as the U.S. index
H5N2 and H5N8 HPAI viruses and a 2005 H5N1 HPAI Gs/GD
lineage virus, with all viruses transmitting efficiently to direct
contacts (1). We demonstrated that both vaccines reduced
significantly, or prevented, virus shedding after challenge in young
ducks. As expected, the best protection occurred with the prime-
boost strategy, which protected most of the ducks against infection.
Antibody titers were not predictive of protection in ducks that
received the single vaccines, with prechallenge HI antibody titers
being undetectable. Boosting with either the same (I-I or A-A) or a
different vaccine (A-I) strategy significantly increased HI titers.
Either way, single or prime-boost vaccination reduced significantly
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Fig. 2. Virus shedding. Swab samples were taken from all ducks at each day after challenge with the A/turkey/Minnesota/12582/15 H5N2
HPAI virus; Log 10 EID50 equivalents were determined by qRRT-PCR; OP ¼ oropharyngeal; CL ¼ cloacal swabs; NV-NC ¼ nonvaccinated
nonchallenged controls; NV-C ¼ nonvaccinated challenged controls. Different superscript lowercase letters denote significant difference for mean
viral titers between groups, P , 0.05. For statistical purposes, all swabs without viral RNA detection were given a numeric value of 2 log 10 EID50
equivalents.
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virus shedding, which would most likely limit virus transmission. It
is commonly observed that viral-vectored vaccines produce low levels
of HI antibody but often provide good protection from challenge in
chickens (Gallus gallus domesticus) (24). This protection is thought
to be from the combined cell-mediated and humoral immunity.
Inactivated vaccines generally produce high levels of HI antibody in
chickens but are not thought to produce protective levels of
cytotoxic T-cell immunity. Therefore, the protection observed from
the single I vaccine, which did not produce detectable HI antibody,
is currently unexplainable. Assays that better correlate the immune
response to vaccination with the outcomes of virus challenge are
needed for ducks. This study confirms results from earlier studies
that show that the antibody response in Pekin ducks is lower than
what is observed in chickens given the same vaccines. To our
knowledge, this is the first study on the use of the alphavirus vaccine
system in ducks, and this challenge suggests that it provides at least
similar protection to inactivated vaccines. Because this was a study of
short duration, we can only speculate if differences in the two types
of vaccine would become more apparent over time.
The protection observed with the vaccines used in this study can
be attributed to the vaccines expressing HA proteins homologous to
the challenge virus (99% similar). Other studies with H5N1 viruses
showed that when the vaccine and the challenge virus belong to the
same H5 subtype and are expected to have high HA homology,
vaccinated ducks were well protected against challenge virus (14).
Genetically more distant vaccines also protected ducks against
infection with H5N1 viruses (14), but previous studies in chickens
demonstrated that antigenically matched vaccines provided superior
protection in a single vaccination strategy, as measured by virus
shedding (4).
The HA of the vaccines used in this study had greater than
98.2% sequence similarity to other Gs/GD H5Nx clade 2.3.4.4A
viruses, but similarity was lower compared with the HA of more
current viruses from clade 2.3.4.4 B, C, and D (,96.8%;
Supplemental Data S1 and Supplemental Fig. S1). A study
examining the antigenic diversity of Asian H5 HPAI viruses also
found that the antigenicity of clade 2.3.4.4 viruses differed slightly
among Groups A, B, and C (11). Although there is a correlation
between genetic and antigenic distance, specific genetic differences
of as little as a single amino acid can lead to a substantial antigenic
differences (20). A study by Peeters et al. examining protection
provided by vaccines against heterologous H5N1 challenge viruses
in chickens found that cross protection correlated better with
genetic variation in selected antigenically relevant residues than in
the complete HA1 protein (17). In any case, genetic and antigenic
differences might affect the efficacy of the vaccines examined in this
study in protecting ducks against infection with more recent H5Nx
clade 2.3.4.4 viruses.
Results from field and laboratory evaluation of vaccines against
H5N1 HPAI in ducks indicates that factors, such as challenge virus,
duck species, vaccination protocols, and proper use of vaccines, may
significantly influence the outcome of the vaccination program.
Other factors, including the role of maternally derived antibodies
and coinfection with other pathogens, remain to be determined in
ducks. Better matching of vaccines with circulating viruses,
optimized vaccines, and vaccination programs should improve the
results of influenza immunization in ducks. Greater attention to
duck vaccination has to be considered if eradication of H5Nx HPAI
is the ultimate goal.
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